Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. develops immuno-pharma therapeutics led by Ampligen (rintatolimod), a dsRNA and selective TLR3 agonist immuno-modulator under development for late-stage pancreatic cancer and other cancer, viral disease and immune-disorder indications. Company news commonly covers clinical disclosures for Ampligen, including pancreatic cancer studies with checkpoint inhibitors, intellectual-property approvals, and regulatory designations.
Updates also address financing and capital-structure actions, such as rights offerings, preferred stock and warrant terms, at-the-market equity arrangements, shareholder voting matters, governance disclosures, operating results, and public-company reporting matters including audit and going-concern disclosures.
AIM ImmunoTech (NYSE American:AIM) announced its participation in The LD 500 Investor conference, taking place virtually from September 1-4, 2020. CEO Thomas K. Equels is scheduled to present on September 1st at 1:20 p.m. Eastern Time. The presentation will be live-streamed on the event's platform. One-on-one meetings with AIM are available through video calls. The LD 500 features prominent small and micro-cap companies, along with keynotes from industry leaders. Interested parties can register via provided links or contact details.
AIM ImmunoTech (NYSE American: AIM) reported a significant increase in cash, reaching $40.3 million as of June 30, 2020, compared to $8.8 million at year-end 2019. The company's R&D expenses rose to $1.46 million from $1.10 million year-over-year. AIM is progressing with a Phase 1/2a trial of Ampligen combined with interferon alfa-2b for cancer patients with COVID-19, supported by agreements with key institutions. The company also aims to address post-COVID-19 chronic fatigue-like illnesses. AIM is pursuing approvals and launches for Ampligen in multiple markets.
AIM ImmunoTech (NYSE American:AIM) announced significant updates in its second-quarter 2020 report. The company's cash reserves increased to $40.3 million from $8.8 million at the end of 2019. Research and development expenses rose to $1.46 million, while general and administrative costs decreased to $1.72 million. AIM is engaged in various clinical trials, including a Phase 1/2a trial of Ampligen for cancer patients with COVID-19, and is collaborating with multiple institutions for further research into Ampligen's potential as a treatment and vaccine adjuvant.